Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

European Commission approves potential new treatment for Pompe disease

Nexviadyme is the first and only newly approved medicine for Pompe disease in Europe in over 15 years

- PMLiVE

Connect to the conversation around mental health: A spotlight on physician burnout

For more than 2 years, the COVID-19 pandemic has put emphasis on an issue that has long affected healthcare workers and physicians -- burnout. Every year, Medscape surveys thousands of...

Medscape Education

- PMLiVE

How understanding the rare disease patient’s lived experience creates better health communications

By Emily Wigginton

- PMLiVE

Collaborating to define patient-centred PROs for mutual benefit

By Ben Johnson (pictured left), Emily Thompson (pictured centre) and Jo Fearnhead-Wymbs (pictured right)

Virtual MSL/Sales training programs and events

Top 10 ways to leverage the Impetus InSite Platform® for internal MSL/Sales training programs and events

Impetus Digital

- PMLiVE

6 trends shaping the future of personalized medicine

Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators.

Avalere Health

- PMLiVE

Omnichannel strategies to revolutionize the healthcare professional experience

Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...

Avalere Health

- PMLiVE

The digital-first launch: the key to connected stakeholder experiences?

During the COVID-19 pandemic, a new digital-first launch model emerged as a gamechanger for driving better customer experiences. Here, Senior Consultant Srividya Sekar; Senior Associate Consultant, Erin Johnstone; and Associate...

Avalere Health

- PMLiVE

Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine

Preliminary laboratory studies show both vaccines neutralise Omicron BA.4 and BA.5

- PMLiVE

Bristol Myers Squibb announces positive trial results for treatment of MS

In the two phase 3 trials, Zeposia treatment showed improved or preserved cognitive function in the majority of patients

- PMLiVE

‘The man behind the mouse’: bringing courage to creativity in healthcare communications

By Aaron Hall

- PMLiVE

My journey advancing the science in pulmonary hypertension

By Neil Davie

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links